Skip to content
10-Q

Quarterly Report

Karyopharm Therapeutics Inc. KPTI

0001193125-25-261667

← back to feed
Filed
Nov 3, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2025 · Oct 30, 2025 17.05B sh
Shares Diluted Q3 2025 · Sep 30, 2025 8.67K sh
Shares Diluted Q3 2025 · Sep 30, 2025 8.59K sh
Shares Diluted restated Q3 2025 · Sep 30, 2024 8.34K sh
Shares Diluted restated Q3 2025 · Sep 30, 2024 8.44K sh
Capex Q3 2025 · Sep 30, 2025 $0
Capex Q3 2025 · Sep 30, 2024 $195K
Operating Cash Flow Q3 2025 · Sep 30, 2025 −$63.54M
Operating Cash Flow Q3 2025 · Sep 30, 2024 −$101.68M
Cash And Equivalents Q3 2025 · Sep 30, 2025 $37.67M
Cash And Equivalents Q3 2025 · Dec 31, 2024 $62.48M
Cash And Equivalents Q3 2025 · Sep 30, 2024 $72.83M
Stockholders Equity Q3 2025 · Sep 30, 2025 −$269.26M
Stockholders Equity Q3 2025 · Jun 30, 2025 −$238.93M
Stockholders Equity Q3 2025 · Dec 31, 2024 −$186.02M
Stockholders Equity Q3 2025 · Sep 30, 2024 −$159.65M
Stockholders Equity Q3 2025 · Jun 30, 2024 −$132.14M
Stockholders Equity Q3 2025 · Dec 31, 2023 −$136.21M
Current Liabilities Q3 2025 · Sep 30, 2025 $87.16M
Current Liabilities Q3 2025 · Dec 31, 2024 $92.26M
Total Liabilities Q3 2025 · Sep 30, 2025 $365.49M
Total Liabilities Q3 2025 · Dec 31, 2024 $350.44M
Current Assets Q3 2025 · Sep 30, 2025 $89.75M
Current Assets Q3 2025 · Dec 31, 2024 $156.46M
Total Assets Q3 2025 · Sep 30, 2025 $96.23M
Total Assets Q3 2025 · Dec 31, 2024 $164.42M
Eps Diluted Q3 2025 · Sep 30, 2025 −$3.82
Eps Diluted Q3 2025 · Sep 30, 2025 −$10.93
Eps Diluted restated Q3 2025 · Sep 30, 2024 −$3.85
Eps Diluted restated Q3 2025 · Sep 30, 2024 −$10.40
Eps Basic Q3 2025 · Sep 30, 2025 −$3.82
Eps Basic Q3 2025 · Sep 30, 2025 −$10.93
Eps Basic restated Q3 2025 · Sep 30, 2024 −$3.85
Eps Basic restated Q3 2025 · Sep 30, 2024 −$5.68
Sga Expense Q3 2025 · Sep 30, 2025 $26.61M
Sga Expense Q3 2025 · Sep 30, 2025 $82.44M
Sga Expense Q3 2025 · Sep 30, 2024 $27.63M
Sga Expense Q3 2025 · Sep 30, 2024 $88.25M
Rd Expense Q3 2025 · Sep 30, 2025 $30.54M
Rd Expense Q3 2025 · Sep 30, 2025 $97.95M
Rd Expense Q3 2025 · Sep 30, 2024 $36.13M
Rd Expense Q3 2025 · Sep 30, 2024 $109.93M
Net Income Q3 2025 · Sep 30, 2025 −$33.13M
Net Income Q3 2025 · Sep 30, 2025 −$93.84M
Net Income Q3 2025 · Sep 30, 2024 −$32.07M
Net Income Q3 2025 · Sep 30, 2024 −$45.64M
Operating Income Q3 2025 · Sep 30, 2025 −$15.22M
Operating Income Q3 2025 · Sep 30, 2025 −$72.86M
Operating Income Q3 2025 · Sep 30, 2024 −$26.28M
Operating Income Q3 2025 · Sep 30, 2024 −$88.16M
Revenue Q3 2025 · Sep 30, 2025 $44.04M
Revenue Q3 2025 · Sep 30, 2025 $111.99M
Revenue Q3 2025 · Sep 30, 2024 $38.78M
Revenue Q3 2025 · Sep 30, 2024 $114.7M